[Modification of blood coagulation by the anti-arrhythmia drug prajmalium bitartrate in vivo].
We studied the effects of prajmaliumbitartrate (PBT, Neo-Gilurytmal, Giulini Pharma, Hannover, FRG), an antiarrhythmic drug on some parameters of blood coagulation in patients. PBT, 20 mg given three times a day, significantly prolonged template bleeding time and ex vivo thrombus formation time in a modified Chandler's loop. Ex vivo platelet aggregation using different agonists and tests of the plasmatic coagulation system remained unchanged.
Riess
H
H
Medizinische Kliniken III, Ludwig-Maximilians-Universität, München.
Bauer
F
F
Hoffmann
E
E
Steinbeck
G
G
Hiller
E
E
D000404:Ajmaline / Q000031:analogs & derivatives*; D001145:Arrhythmias, Cardiac / Q000097:blood / Q000188:drug therapy*; D001760:Bleeding Time; D001780:Blood Coagulation Tests; D006801:Humans; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects; D010979:Platelet Function Tests; D011219:Prajmaline / Q000627:therapeutic use*
D000404:Ajmaline; D011219:Prajmaline
Beeinflussung der Blutgerinnung durch das Antiarrhythmikum Prajmaliumbitartrat in vivo.